Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results

Autor: H. Durnall, B. Smyth, Douglas M. Fleming, Joanna Ellis, Nick Andrews, Maria Zambon, Angie Lackenby, Chris Robertson, Simon Cottrell, Catherine Moore, Rory Gunson, B. Von Wissmann, Jim McMenamin, Richard Pebody
Přispěvatelé: Coppens, Kim, Health Protection Scotland, International Prevention Research Institute (IPRI), University of Strathclyde [Glasgow]
Rok vydání: 2014
Předmět:
Male
Time Factors
Epidemiology
Prevalence
medicine.disease_cause
0302 clinical medicine
Influenza A Virus
H1N1 Subtype
Influenza A virus
Medicine
030212 general & internal medicine
Child
0303 health sciences
Adolescent Adult Aged Case-Control Studies Child Female Great Britain/epidemiology Hemagglutination Inhibition Tests Humans Influenza A Virus
Reverse Transcriptase Polymerase Chain Reaction
Vaccination
virus diseases
Middle Aged
3. Good health
Treatment Outcome
Influenza Vaccines
Female
Sample collection
Seasons
Adult
Adolescent
Influenza vaccine
Human/*epidemiology/immunology/*prevention & control/virology Male Middle Aged Primary Health Care Reverse Transcriptase Polymerase Chain Reaction Seasons *Sentinel Surveillance Sequence Analysis
Antigenic drift
Virus
DNA Time Factors Treatment Outcome Vaccination/statistics & numerical data
03 medical and health sciences
Virology
Influenza
Human
Humans
Aged
H1N1 Subtype/classification/genetics/immunology/*isolation & purification Influenza A Virus
Primary Health Care
030306 microbiology
business.industry
Influenza A Virus
H3N2 Subtype
Public Health
Environmental and Occupational Health
H3N2 Subtype/classification/genetics/immunology/*isolation & purification Influenza B virus/genetics/*immunology/isolation & purification Influenza Vaccines/*administration & dosage/immunology/therapeutic use Influenza
Sequence Analysis
DNA
Hemagglutination Inhibition Tests
United Kingdom
Influenza B virus
Immunization
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie
Case-Control Studies
[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
business
Sentinel Surveillance
Zdroj: Europe PubMed Central
Scopus-Elsevier
Euro Surveill
Euro Surveill, 2014, 19 (27), pp.5-13
ISSN: 1560-7917
Popis: Andrews, N McMenamin, J Durnall, H Ellis, J Lackenby, A Robertson, C von Wissmann, B Cottrell, S Smyth, B Moore, C Gunson, R Zambon, M Fleming, D Pebody, R eng Research Support, Non-U.S. Gov't Sweden 2014/07/18 06:00 Euro Surveill. 2014 Jul 10;19(27):5-13.; International audience; The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a test-negative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14.
Databáze: OpenAIRE
Externí odkaz: